EVel magnetic bead, preparation method and application of EVel magnetic bead in extraction of plasma extracellular vesicles

By modifying the EVlent magnetic beads of CD9, CD63 and CD81 antibodies on the surface of the magnetic beads, the contamination problem during EVs separation in plasma is solved, and EVs capture with efficient and proteomic analysis is achieved, which improves the separation efficiency and purity. It is suitable for Diversity analysis.

CN118904309APending Publication Date: 2024-11-08NANJING EVLIXIR BIOTECH INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411047542.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-01
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The prior art High abundance of albumin and lipoprotein particle contamination in the isolation of extracellular vesicles (EVs) from plasma leads to negative effects of proteomic analysis, and the existing methods are complex, time-consuming and incompatible with nanometers. Particle tracking analysis and proteomic analysis.

Method used

Develop an EVlent magnetic bead that is used to efficiently capture plasma by modifying tetraspan-membrane protein antibodies, including CD9, CD63 and CD81 on the surface of the magnetic beads. EVs were directly cleaved in situ to compatible with proteomic analysis.

Benefits of technology

It improves the capture efficiency and purity of EVs, enhances the ability to explore and analyze vesicle diversity, reduces sample loss, is compatible with proteomic analysis, and improves separation efficiency and sensitivity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118904309A_ABST
    Figure CN118904309A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of extracellular vesicle separation and proteomics. The invention particularly relates to an EVel magnetic bead, a preparation method and application of the EVel magnetic bead in extraction of plasma extracellular vesicles. The EVent magnetic bead comprises a magnetic bead body and a biomarker modified on the outer surface of the magnetic bead body, the biomarker is a four-transmembrane protein antibody and comprises CD9, CD63 and CD81, and the content ratio of the CD9 to the CD63 to the CD81 is (30%-80%): (10%-50%): (10%-50%). The preparation method comprises the following steps: S1, taking carboxyl magnetic beads, cleaning the carboxyl magnetic beads for three times by using a coating solution, then adding an EDC solution and an NHS solution to resuspend the carboxyl magnetic beads, and then placing the magnetic bead suspension on a stirrer to be fully and uniformly mixed to obtain activated magnetic beads; s2, cleaning the activated magnetic beads by using a coating solution for at least three times, then adding CD9, CD63 and CD81 antibodies, and uniformly mixing at room temperature to react for 4-6 hours; after the reaction is finished, cleaning the magnetic beads for 2-3 times by using a confining liquid, adding the confining liquid, and stirring at room temperature for 12 hours; and after stirring is finished, removing the confining liquid by using a magnetic separation method to obtain the EVel magnetic beads.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of extracellular vesicle separation and proteomics, and specifically relates to an EVlent magnetic bead, a preparation method and an application in extracting extracellular vesicles from plasma. Background Art

[0002] Extracellular vesicles (EVs) are nanoscale vesicles secreted by most cells. They are composed of a phospholipid bilayer structure. As an important tool for intercellular communication, EVs contain a variety of biological molecules such as proteins, lipids, RNA and DNA. These vesicles play a role in a variety of physiological processes, such as immune response, tissue repair, blood coagulation, and disease-related processes, including cancer metastasis and inflammation. Their diversity and complexity have made EVs a hot topic in biomedical research, especially in the development of disease diagnosis and treatment strategies.

[0003] Plasma-derived extracellular vesicles (EVs) are an important source of biomarkers. Currently, it remains a challenge to isolate EVs from small amounts of human plasma for downstream proteomic analysis. The separation process is hampered by contamination with highly abundant albumin and lipoprotein particles, which negatively impacts proteomic analysis. Although there are a variety of methods for isolating and purifying EVs from plasma, such as ultracentrifugation, precipitation, size exclusion chromatography, and immunoaffinity, there are still some challenges in the isolation of plasma EVs. Ultracentrifugation: The method is time-consuming and complex to operate, requiring multiple centrifugation steps, each of which may take several hours; sample loss and contamination, a portion of EVs may be lost during centrifugation, while other non-EVs particles may be captured; large batch-to-batch variation, and differences in operator operation may lead to inconsistent results. Precipitation method: Low purity, precipitation usually cannot guarantee high-purity samples, because the precipitate may include multiple types of biological particles and impurities; sample loss, part of the target substance may be lost during precipitation, especially during multiple washing and transfer processes; this loss may lead to reduced sensitivity of subsequent analysis. Size exclusion chromatography: The separation efficiency is not high and may not completely remove all small molecule contaminants; sample dilution, EVs may be diluted during processing, affecting subsequent analysis. Although immunoaffinity-based magnetic beads have been developed, EV immunoisolation by magnetic beads is usually combined with flow sorting and western blotting (WB), but it lacks compatibility with nanoparticle tracking analysis (NTA) or proteomics analysis. Summary of the invention

[0004] In view of the shortcomings of the prior art, the purpose of the present invention can be achieved through the following technical solutions:

[0005] A kind of EVlent magnetic bead, the EVlent magnetic bead comprises a magnetic bead body and a biomarker modified on the outer surface of the magnetic bead body, the biomarker is a tetraspanin antibody, including CD9, CD63 and CD81, wherein the content proportion of CD9, CD63 and CD81 is: 30%-80%: 10%-50%: 10%-50%.

[0006] A method for preparing EVlent magnetic beads, the method comprising the following steps: S1, taking carboxyl magnetic beads and washing them three times with a coating solution, then adding an EDC solution and an NHS solution to resuspend the carboxyl magnetic beads, and then placing the magnetic bead suspension on a stirrer to fully mix to obtain activated magnetic beads;

[0007] S2. Wash the activated magnetic beads with coating solution for at least 3 times, then add CD9, CD63 and CD81 antibodies, mix and react at room temperature for 4-6 hours; after the reaction, wash the magnetic beads with blocking solution for 2-3 times, then add blocking solution and stir at room temperature for 12 hours; after stirring, use magnetic separation method to remove the blocking solution to obtain EVlent magnetic beads.

[0008] Furthermore, in step S1, the volume ratio of the EDC solution to the NHS solution is 1:1.

[0009] Furthermore, in step S2, the added amounts of CD9, CD63 and CD81 antibodies are 30%-80%: 10%-50%: 10%-50%.

[0010] The EVlent magnetic beads described above are used to extract extracellular vesicles from plasma.

[0011] Furthermore, the specific steps of using EVlent magnetic beads to extract extracellular vesicles from plasma are as follows: take a plasma sample, dilute it 10 times with Loading Buffer solution, add EVlent magnetic beads and incubate at room temperature for 1 hour, and remove the supernatant by magnetic separation; then, wash once with Loading Buffer solution and twice with 1xPBS solution; then elute EVlent magnetic beads twice with eluent to extract extracellular vesicles from plasma.

[0012] Furthermore, the volume ratio of the plasma sample and EVlent magnetic beads is 1:2-5:1.

[0013] Furthermore, the eluent is a triethylamine solution with a concentration of 100 mM and a dosage of 200 μL.

[0014] Beneficial effects of the present invention: The advantages of the magnetic beads modified with multiple antibodies proposed in the present invention are: ① Enhanced capture range: By combining multiple antibodies, multiple vesicles expressing different markers can be captured simultaneously, increasing the comprehensiveness and coverage of the capture, and suitable for exploring and analyzing the diversity of vesicles; ② Improved capture efficiency: The combination of multiple antibodies can improve the overall capture efficiency of vesicles, especially when a single marker is not sufficient to represent all relevant vesicles; ③ Flexibility: Different antibody combinations can be selected according to the research purpose, and the composition of the magnetic beads can be flexibly adjusted to adapt to different experimental conditions and goals. At the same time, after capturing EVs in plasma, we directly perform in situ lysis to avoid sample loss caused by the elution method. This method is well compatible with proteomics analysis. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, for ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.

[0016] Figure 1 This is the separation and proteomic analysis of plasma EVs based on EVlent in the present invention.

[0017] Figure 2 (AB) are the analysis of the recovery efficiency by isolating EVs in PBS and detecting CD9 using western blotting (the purified original EVs were used as the EVs standard solution for the recovery experiment); (C) is the comparison of EVs captured in plasma by different methods; (D) is the grayscale value of the CD9 band obtained by different methods.

[0018] Figure 3 Proteomic analysis of EVs separated by different methods in the present invention. (A) Complete proteome separated by different methods; (B) Increased proteomic intensity of 10 EV proteins in LC-MS data compared with UC samples (left), and decreased proteomic intensity of 4 common contaminant proteins (right).

[0019] Figure 4 This is the proteomic analysis of EVs separated from different plasma volumes in the present invention.

[0020] Figure 5Identification of EVs isolated from plasma in the present invention. (A) Western blotting results of plasma EVs isolated from UC and EVlent. Cell extracts were used as controls. CD9, CD81 and HSP70 were selected as biomarkers of EVs, and Calnexin was used as a negative control; (B) NTA results of plasma EVs isolated from UC and EVlent; (C, D) TEM images of plasma EVs isolated from EVlent. DETAILED DESCRIPTION

[0021] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0022] Capture of extracellular vesicles with affinity magnetic beads: Take 200μL plasma sample, dilute 10 times with Loading Buffer, add 40μL EVlent magnetic beads, incubate at room temperature for 1 hour, and remove the supernatant by magnetic separation. Subsequently, wash once with 1mL Loading Buffer and twice with 1mL 1xPBS solution. Finally, elute EVlent magnetic beads twice with 200μL eluent (100mM triethylamine solution) to obtain EVs. The obtained EVs can be used for downstream WB, NTA and TEM experiments.

[0023] Proteomic analysis: After enriching extracellular vesicles with affinity magnetic beads, 100 μL of PTS lysis solution was added for in situ treatment, and the mixture was incubated in a 95°C water bath for 10 min; cooled to room temperature, 450 μL of 50 mM TEAB buffer was added; then, Lys-C enzyme was added according to the sample protein content: enzyme = 100:1, and incubated at 37°C for 3 hours; then, trypsin enzyme was added according to the sample protein content: trypsin = 50:1, and incubated at 37°C overnight; after incubation overnight, 50 μL of 10% TFA was added to terminate the enzymatic hydrolysis; 5 times the volume of ethyl acetate was added, vortexed for 2 min, centrifuged at 20,000 g for 3 min, the supernatant was removed, and repeated once; the samples were lyophilized, and the samples were desalted and subjected to mass spectrometry detection.

[0024] Example 1: First, take 10 mg of carboxyl magnetic beads and wash them 3 times with coating solution. Then resuspend 10 mg of magnetic beads with 0.5 mL of EDC and 0.5 mL of NHS solution, and place the magnetic bead suspension on a stirrer to mix thoroughly, react for 1-2 hours, and activate the magnetic beads. The activated magnetic beads are washed 3 times with coating solution. Then, the three antibodies are added to 1 mL of resuspended magnetic beads containing 10 mg according to CD9:CD63:CD81=1:1:1, and mixed and reacted at room temperature for 4-6 hours. After the reaction, wash the magnetic beads 2-3 times with blocking solution, 1 mL each time. Then, add 1 mL of blocking solution and stir at room temperature for 12 hours. Finally, remove the blocking solution by magnetic separation, and preserve the functionalized magnetic beads with magnetic bead preservation solution at a concentration of 10 mg / mL. Take 200 μL of plasma, use the magnetic beads to enrich EVs, and the EVs after separation are eluted with elution solution, and the obtained EVs are used for downstream analysis. When performing proteomic analysis, EVs are directly lysed in situ after enrichment, enzymatically digested, desalted, and detected by mass spectrometry.

[0025] Comparative Example 1: First, take 10 mg of carboxyl magnetic beads and wash them 3 times with coating solution. Then resuspend 10 mg of magnetic beads with 0.5 mL of EDC and 0.5 mL of NHS solution, and place the magnetic bead suspension on a stirrer to mix thoroughly, react for 1-2 hours, and activate the magnetic beads. The activated magnetic beads are washed 3 times with coating solution. Then, an appropriate amount of anti-CD9 antibody is added to 1 mL of resuspended magnetic beads containing 10 mg, and the reaction is mixed at room temperature for 4-6 hours. After the reaction, wash the magnetic beads 2-3 times with blocking solution, 1 mL each time. Then, add 1 mL of blocking solution and stir at room temperature for 12 hours. Finally, remove the blocking solution by magnetic separation, and preserve the functionalized magnetic beads with magnetic bead preservation solution at a concentration of 10 mg / mL. Take 200 μL of plasma, use the magnetic beads to enrich EVs, and after separation, EVs are eluted with elution solution, and the obtained EVs are used for downstream analysis. When performing proteomic analysis, EVs are directly lysed in situ after enrichment, enzymatically digested, desalted, and detected by mass spectrometry.

[0026] Comparative Example 2: First, take 10 mg of carboxyl magnetic beads and wash them 3 times with coating solution. Then resuspend 10 mg of magnetic beads with 0.5 mL of EDC and 0.5 mL of NHS solution, and place the magnetic bead suspension on a stirrer to mix thoroughly, react for 1-2 hours, and activate the magnetic beads. The activated magnetic beads are washed 3 times with coating solution. Then, an appropriate amount of anti-CD63 antibody is added to 1 mL of resuspended magnetic beads containing 10 mg, and the reaction is mixed at room temperature for 4-6 hours. After the reaction, wash the magnetic beads 2-3 times with blocking solution, 1 mL each time. Then, add 1 mL of blocking solution and stir at room temperature for 12 hours. Finally, remove the blocking solution by magnetic separation, and preserve the functionalized magnetic beads with magnetic bead preservation solution at a concentration of 10 mg / mL. Take 200 μL of plasma, use the magnetic beads to enrich EVs, and after separation, EVs are eluted with elution solution, and the obtained EVs are used for downstream analysis. When performing proteomic analysis, EVs are directly lysed in situ after enrichment, enzymatically digested, desalted, and detected by mass spectrometry.

[0027] Comparative Example 3: First, take 10 mg of carboxyl magnetic beads and wash them 3 times with coating solution. Then resuspend 10 mg of magnetic beads with 0.5 mL of EDC and 0.5 mL of NHS solution, and place the magnetic bead suspension on a stirrer to mix thoroughly, react for 1-2 hours, and activate the magnetic beads. The activated magnetic beads are washed 3 times with coating solution. Then, an appropriate amount of anti-CD81 antibody is added to 1 mL of resuspended magnetic beads containing 10 mg, and the reaction is mixed at room temperature for 4-6 hours. After the reaction, wash the magnetic beads 2-3 times with blocking solution, 1 mL each time. Then, add 1 mL of blocking solution and stir at room temperature for 12 hours. Finally, remove the blocking solution by magnetic separation, and preserve the functionalized magnetic beads with magnetic bead preservation solution at a concentration of 10 mg / mL. Take 200 μL of plasma, use the magnetic beads to enrich EVs, and after separation, EVs are eluted with elution solution, and the obtained EVs are used for downstream analysis. When performing proteomic analysis, EVs are directly lysed in situ after enrichment, enzymatically digested, desalted, and detected by mass spectrometry.

[0028] Comparative Example 4: Take 200 μL of plasma, dilute 10 times with pre-cooled PBS (4°C), and centrifuge at 10,000g for 1 hour. Subsequently, the supernatant was centrifuged at 100,000g for 70 minutes at 4°C. After removing the supernatant, add pre-cooled PBS to resuspend the microspheres and centrifuge again at 100,000g for 70 minutes. Finally, the washed EVs microspheres were collected for further experiments and downstream analysis.

[0029] We first prepared four types of affinity magnetic beads: three were modified with anti-CD9 (Comparative Example 1), CD63 (Comparative Example 2), and CD81 (Comparative Example 3) antibodies, and the fourth (Example 1) was modified with all three antibodies at the same time, and the traditional UC separation method (Comparative Example 4) was used as a comparison. We compared the efficiency of UC and the four magnetic beads in separating EVs from PBS solution by WB method. Figure 2 As shown in A-2B, after measuring the CD9 band intensity, the order of EV separation efficiency obtained was CD9 / CD63 / CD81 (85.6%) > CD9 (81.3%) > CD81 (79.2%) > CD63 (63.6%) > UC (17.8%), indicating that the anti-CD9 / CD63 / CD81 affinity magnetic beads had the highest separation rate and UC had the worst. Subsequently, the separation effect of affinity magnetic beads in actual biological samples was evaluated. 200 μL of plasma was incubated with 4 different magnetic beads. After incubation, wash once with 0.01% Triton100 and twice with PBS. Then, WB was used to test the 4 different magnetic beads to observe the effect of different magnetic beads in capturing EVs in plasma, with the UC method as a control. Figure 2 C-2D analysis showed that the affinity magnetic beads modified with three antibodies had the best effect, followed by magnetic beads modified with anti-CD9, anti-CD81 and anti-CD63 antibodies, and the UC method had the worst effect. In summary, the magnetic beads modified with three antibodies had better effects, which may be related to the synergistic effect of different antibody capture.

[0030] Comparative Example 5: Different plasma volumes (5 μL, 10 μL, 20 μL, 50 μL, 100 μL, 150 μL, 200 μL) of plasma were taken respectively, and appropriate amounts of magnetic beads of Example 1 (plasma: magnetic beads = 1:2-1:5) were added to enrich EVs, and the enriched EVs were directly lysed in situ, enzymatically hydrolyzed, desalted and detected by mass spectrometry.

[0031] Comparative Example 6: First, take 10 mg of carboxyl magnetic beads and wash them 3 times with coating solution. Then resuspend 10 mg of magnetic beads with 0.5 mL of EDC and 0.5 mL of NHS solution, and place the magnetic bead suspension on a stirrer to mix thoroughly, react for 1-2 hours, and activate the magnetic beads. The activated magnetic beads are washed 3 times with coating solution. Then, the three antibodies are added to 1 mL of resuspended magnetic beads containing 10 mg according to CD9:CD63:CD81=3:1:1, and mixed at room temperature for 4-6 hours. After the reaction, wash the magnetic beads 2-3 times with blocking solution, 1 mL each time. Then, add 1 mL of blocking solution and stir at room temperature for 12 hours. Finally, remove the blocking solution by magnetic separation, and preserve the functionalized magnetic beads with magnetic bead preservation solution at a concentration of 10 mg / mL. Take 200 μL of plasma, use the magnetic beads to enrich EVs, and elute the EVs after separation with elution solution, and the obtained EVs are used for downstream analysis. When performing proteomic analysis, EVs are directly lysed in situ after enrichment, enzymatically digested, desalted, and detected by mass spectrometry.

[0032] Comparative Example 7: First, take 10 mg of carboxyl magnetic beads and wash them 3 times with coating solution. Then resuspend 10 mg of magnetic beads with 0.5 mL of EDC and 0.5 mL of NHS solution, and place the magnetic bead suspension on a stirrer to mix thoroughly, react for 1-2 hours, and activate the magnetic beads. The activated magnetic beads are washed 3 times with coating solution. Then, the three antibodies are added to 1 mL of resuspended magnetic beads containing 10 mg according to CD9:CD63:CD81=6:1:1, and mixed at room temperature for 4-6 hours. After the reaction, wash the magnetic beads 2-3 times with blocking solution, 1 mL each time. Then, add 1 mL of blocking solution and stir at room temperature for 12 hours. Finally, remove the blocking solution by magnetic separation, and preserve the functionalized magnetic beads with magnetic bead preservation solution at a concentration of 10 mg / mL. Take 200 μL of plasma, use the magnetic beads to enrich EVs, and the EVs after separation are eluted with elution solution, and the obtained EVs are used for downstream analysis. When performing proteomic analysis, EVs are directly lysed in situ after enrichment, enzymatically digested, desalted, and detected by mass spectrometry.

[0033] Comparative Example 8: First, take 10 mg of carboxyl magnetic beads and wash them 3 times with coating solution. Then resuspend 10 mg of magnetic beads with 0.5 mL of EDC and 0.5 mL of NHS solution, and place the magnetic bead suspension on a stirrer to mix thoroughly, react for 1-2 hours, and activate the magnetic beads. The activated magnetic beads are washed 3 times with coating solution. Then, the three antibodies are added to 1 mL of resuspended magnetic beads containing 10 mg according to CD9:CD63:CD81=1:3:1, and mixed at room temperature for 4-6 hours. After the reaction, wash the magnetic beads 2-3 times with blocking solution, 1 mL each time. Then, add 1 mL of blocking solution and stir at room temperature for 12 hours. Finally, remove the blocking solution by magnetic separation, and preserve the functionalized magnetic beads with magnetic bead preservation solution at a concentration of 10 mg / mL. Take 200 μL of plasma, use the magnetic beads to enrich EVs, and elute the EVs after separation with elution solution, and the obtained EVs are used for downstream analysis. When performing proteomic analysis, EVs are directly lysed in situ after enrichment, enzymatically digested, desalted, and detected by mass spectrometry.

[0034] Comparative Example 9: First, take 10 mg of carboxyl magnetic beads and wash them 3 times with coating solution. Then resuspend 10 mg of magnetic beads with 0.5 mL of EDC and 0.5 mL of NHS solution, and place the magnetic bead suspension on a stirrer to mix thoroughly, react for 1-2 hours, and activate the magnetic beads. The activated magnetic beads are washed 3 times with coating solution. Then, the three antibodies are added to 1 mL of resuspended magnetic beads containing 10 mg according to CD9:CD63:CD81=1:6:1, and mixed at room temperature for 4-6 hours. After the reaction, wash the magnetic beads 2-3 times with blocking solution, 1 mL each time. Then, add 1 mL of blocking solution and stir at room temperature for 12 hours. Finally, remove the blocking solution by magnetic separation, and preserve the functionalized magnetic beads with magnetic bead preservation solution at a concentration of 10 mg / mL. Take 200 μL of plasma, use the magnetic beads to enrich EVs, and the EVs after separation are eluted with elution solution, and the obtained EVs are used for downstream analysis. When performing proteomic analysis, EVs are directly lysed in situ after enrichment, enzymatically digested, desalted, and detected by mass spectrometry.

[0035] Comparative Example 10: First, take 10 mg of carboxyl magnetic beads and wash them 3 times with coating solution. Then resuspend 10 mg of magnetic beads with 0.5 mL of EDC and 0.5 mL of NHS solution, and place the magnetic bead suspension on a stirrer to mix thoroughly, react for 1-2 hours, and activate the magnetic beads. The activated magnetic beads are washed 3 times with coating solution. Then, the three antibodies are added to 1 mL of resuspended magnetic beads containing 10 mg according to CD9:CD63:CD81=1:1:3, and mixed at room temperature for 4-6 hours. After the reaction, wash the magnetic beads 2-3 times with blocking solution, 1 mL each time. Then, add 1 mL of blocking solution and stir at room temperature for 12 hours. Finally, remove the blocking solution by magnetic separation, and preserve the functionalized magnetic beads with magnetic bead preservation solution at a concentration of 10 mg / mL. Take 200 μL of plasma, use the magnetic beads to enrich EVs, and elute the EVs after separation with elution solution, and the obtained EVs are used for downstream analysis. When performing proteomic analysis, EVs are directly lysed in situ after enrichment, enzymatically digested, desalted, and detected by mass spectrometry.

[0036] Comparative Example 11: First, take 10 mg of carboxyl magnetic beads and wash them 3 times with coating solution. Then resuspend 10 mg of magnetic beads with 0.5 mL of EDC and 0.5 mL of NHS solution, and place the magnetic bead suspension on a stirrer to mix thoroughly, react for 1-2 hours, and activate the magnetic beads. The activated magnetic beads are washed 3 times with coating solution. Then, the three antibodies are added to 1 mL of resuspended magnetic beads containing 10 mg according to CD9:CD63:CD81=1:1:6, and mixed at room temperature for 4-6 hours. After the reaction, wash the magnetic beads 2-3 times with blocking solution, 1 mL each time. Then, add 1 mL of blocking solution and stir at room temperature for 12 hours. Finally, remove the blocking solution by magnetic separation, and preserve the functionalized magnetic beads with magnetic bead preservation solution at a concentration of 10 mg / mL. Take 200 μL of plasma, use the magnetic beads to enrich EVs, and elute the EVs after separation with elution solution, and the obtained EVs are used for downstream analysis. When performing proteomic analysis, EVs are directly lysed in situ after enrichment, enzymatically digested, desalted, and detected by mass spectrometry.

[0037] To further evaluate the effect of magnetic beads with different affinities, we compared this method with the traditional UC method. Five plasma samples were taken, each with 200 μL. Different magnetic beads and UC were used to isolate EVs from plasma. After separation, EVs were pretreated and analyzed by LC-MS. The identification results are as follows ( Figure 3 As shown in the figure, the magnetic beads modified with three antibodies have the best identification quantity, and the UC method is the worst ( Figure 3 A). It is noteworthy that various EVs purification techniques are susceptible to contamination by non-EVs plasma components (such as plasma proteins, complement factors, and immunoglobulins), especially those that rely on chemical precipitation and precipitation. Therefore, we evaluated the specificity of four different affinity magnetic beads by comparing the relative intensities of 10 typical EVs proteins and four common plasma proteins in EV samples purified by four different affinity magnetic beads and UC. Figure 3 As shown in B, samples treated with affinity magnetic beads showed higher intensities of EVs markers and related proteins compared with UC. It is worth noting that in most cases, magnetic beads modified with three antibodies showed the highest intensity. In addition, the intensity of four common contaminants in affinity magnetic beads was significantly reduced compared with the traditional UC separation method. When a single modified affinity magnetic bead is used for enrichment, non-expressed or low-expressed EVs may be missed. When multiple antibodies are used, EVs in the sample can be enriched more comprehensively and the recovery rate can be improved. In summary, affinity magnetic beads modified with three different antibodies perform best.

[0038] like Figure 4As shown in the figure, we used magnetic beads modified with three antibodies to enrich EVs in different plasma volumes and perform proteomic analysis. As the plasma volume increased, the number of identified proteins and peptides gradually increased. When the plasma volume was in the range of 5μL to 100μL, the increase was large. Between 100μL and 200μL, the rate of increase was relatively slow. More than 2,000 proteins and more than 15,000 peptides can be identified using 100μL of plasma, and up to 2,402 proteins and 17,532 peptides can be identified in 200μL of plasma. It is worth noting that even with only 5μL of plasma, more than 800 proteins and more than 5,000 peptides can be identified.

[0039] The ratio of the three antibodies on the affinity beads may affect their ability to capture EVs. In order to improve the performance of the affinity beads, we optimized the ratio of the three antibodies and performed proteomic analysis. The specific identification results are shown in Table 1. From the experimental results, it can be seen that with the increase in the concentration of CD9 antibodies, the number of protein and peptide identifications first increased and then decreased. When the concentrations of CD63 and CD81 antibodies increased, the number of protein and peptide identifications decreased significantly. It can be seen that when the ratio of the three antibodies is 3:1:1, the affinity beads have the best performance. We named the beads EVlent.

[0040] Table 1

[0041]

[0042]

[0043] To further understand the performance of EVlent magnetic beads, we conducted a more systematic evaluation of EVlent magnetic beads. To evaluate the efficacy of EVlent in capturing plasma EVs, we compared it with UC. Three EVs biomarkers were detected by WB: CD9, TSG101, and HSP70. Figure 5 A shows clear bands of CD9, TSG101, and HSP70 in the EVlent channel, while these bands are weak in the UC channel. In addition, no Calnexin protein band was detected in either separation strategy. Subsequently, the separated EVs were analyzed by NTA. Figure 5 As shown in B, the EVs generated by the two methods were mainly in the range of 0-400 nm. The plasma EV concentrations obtained by EVlent and UC were 2.53 x 10 9 and 1.93x 10 9 Particles / mL, indicating that the separation efficiency of EVlent is better than that of UC. Transmission electron microscopy (TEM) was used to further verify the separation of plasma EVs. TEM images ( Figure 5C and 5D) clearly show intact EVs. In summary, EVlent magnetic beads were used to successfully separate EVs from plasma, and the separation efficiency was significantly improved compared with UC.

[0044] In the description of this specification, the description with reference to the terms "one embodiment", "example", "specific example", etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representation of the above terms does not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described can be combined in any one or more embodiments or examples in a suitable manner.

[0045] The above shows and describes the basic principles, main features and advantages of the present invention. Those skilled in the art should understand that the present invention is not limited to the above embodiments, and the above embodiments and descriptions are only for explaining the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, and these changes and improvements all fall within the scope of the present invention to be protected.

Claims

1. An EVlent magnetic bead, characterized in that: The EVlent magnetic beads include a magnetic bead body and a biomarker modified on the outer surface of the magnetic bead body, wherein the biomarker is a tetraspanin antibody, including CD9, CD63 and CD81, wherein the content ratios of CD9, CD63 and CD81 are: 30%-80%: 10%-50%: 10%-50%.

2. A method for preparing EVlent magnetic beads, characterized in that: The preparation method comprises the following steps: S1, taking carboxyl magnetic beads and washing them three times with a coating solution, then adding an EDC solution and an NHS solution to resuspend the carboxyl magnetic beads, and then placing the magnetic bead suspension on a stirrer to fully mix to obtain activated magnetic beads; S2. Wash the activated magnetic beads with coating solution for at least 3 times, then add CD9, CD63 and CD81 antibodies, mix and react at room temperature for 4-6 hours; after the reaction, wash the magnetic beads with blocking solution for 2-3 times, then add blocking solution and stir at room temperature for 12 hours; after stirring, use magnetic separation method to remove the blocking solution to obtain EVlent magnetic beads.

3. A method for preparing EVlent magnetic beads according to claim 2, characterized in that: The volume ratio of the EDC solution to the NHS solution in step S1 is 1:

1.

4. The method for preparing EVlent magnetic beads according to claim 2, characterized in that: In step S2, the added amounts of CD9, CD63 and CD81 antibodies are 30%-80%: 10%-50%: 10%-50%.

5. The EVlent magnetic beads as described in claim 1 are used for extracting extracellular vesicles from plasma.

6. The use according to claim 5, characterized in that The specific steps of using EVlent magnetic beads to extract extracellular vesicles from plasma are as follows: take a plasma sample, dilute it 10 times with Loading Buffer solution, add EVlent magnetic beads and incubate at room temperature for 1 hour, and remove the supernatant by magnetic separation; then, wash once with Loading Buffer solution and twice with 1xPBS solution; then elute EVlent magnetic beads twice with elution solution to extract extracellular vesicles from plasma.

7. The use according to claim 6, characterized in that The volume ratio of the plasma sample and EVlent magnetic beads is 1:2-5:

1.

8. The use according to claim 6, characterized in that The eluent is a triethylamine solution with a concentration of 100 mM and a dosage of 200 μL.